Pfizer (PFE) Peer Comparison
$29.36
$-0.52
(-1.74%)
As on 06-Nov-2026 11:43EST
Market cap
$170,312 Mln
Revenue (TTM)
$63,624 Mln
P/E Ratio
42.7
P/B Ratio
2
Div. Yield
5.6 %
Edit
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
170,312 | 1,206,069 | 655,559 | 509,498 | 362,526 |
Revenue ($ Mln) |
63,624 | 86,462 | 99,335 | 66,014 | 67,302 |
Net Profit ($ Mln) |
4,033.00 | 27,579.70 | 16,095.00 | 10,350.00 | 2,453.00 |
Net Margin (%) |
6.34 | 31.90 | 16.20 | 15.68 | 3.64 |
RoE (%) |
4.46 | 77.18 | 19.78 | -- | 5.41 |
Price to Earnings |
42.69 | 43.95 | 41.32 | 49.53 | 148.42 |
Price-To-Book |
1.97 | 30.19 | 8.16 | 245.29 | 8.85 |
Income Statement ($ Mln)
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
63,624.00 | 86,462.00 | 99,335.00 | 66,014.00 | 67,302.00 |
|
Cost of Revenue
|
16,940.00 | 14,149.70 | 30,982.00 | 15,677.00 | 15,512.00 |
|
Gross Profit
|
46,512.00 | 54,127.00 | 63,937.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
31,520.00 | 32,481.90 | 42,828.00 | 26,879.00 | 40,863.00 |
|
Operating Profit (EBIT)
|
15,164.00 | 39,830.40 | 25,525.00 | 23,458.00 | 10,927.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
4,260.00 | 34,769.20 | 17,737.00 | 12,814.00 | 4,762.00 |
|
Provision for Tax
|
186.00 | 7,189.50 | 1,642.00 | 2,466.00 | 2,313.00 |
|
Profit after Tax (Net Income)
|
4,033.00 | 27,579.70 | 16,095.00 | 10,350.00 | 2,453.00 |
|
Minority Interest
|
-36.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Consolidated Profit
|
-1,648.00 | 6,636.00 | 5,116.00 | 0.00 | 2,963.00 |
Liabilities ($ Mln)
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
89,001.00 | 40,271.00 | 81,529.00 | -5,935.00 | 44,893.00 |
|
Minority Interest
|
-36.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Non-Current Liabilities
|
83,517.00 | 60,805.00 | 60,439.00 | 99,361.00 | 59,026.00 |
|
Current Liabilities
|
31,726.00 | 46,996.00 | 55,457.00 | 41,642.00 | 28,801.00 |
|
Total Liabilities
|
208,160.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
159,536.00 | 82,809.00 | 141,074.00 | 101,446.00 | 93,832.00 |
|
Current Assets
|
45,008.00 | 65,263.00 | 56,351.00 | 33,669.00 | 38,941.00 |
|
Total Assets
|
208,160.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
62,671.00 | 49,503.00 | 44,651.00 | 70,822.00 | 53,777.00 |
|
Net Current Assets
|
13,283.00 | 18,267.00 | 894.00 | -7,973.00 | 10,140.00 |
Cashflow ($ Mln)
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
11,705.00 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-1,351.00 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-10,304.00 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.03 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
4.46 | 77.18 | 19.78 | 6,214.71 | 5.41 |
|
ROA (%)
|
1.67 | 15.75 | 6.48 | 5.85 | 1.53 |
|
EBIT Margin (%)
|
10.95 | 49.24 | 18.85 | 26.50 | 9.28 |
|
Net Margin (%)
|
6.34 | 31.90 | 16.20 | 15.68 | 3.64 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.33 | 45.51 | 7.80 | 10.68 | 4.79 |
|
EBIT Growth (%)
|
-41.21 | 70.32 | -41.80 | 285.20 | -72.96 |
|
Net Profit Growth (%)
|
-58.96 | 49.79 | -35.92 | 333.42 | -87.11 |
|
EPS Growth (%)
|
-59.38 | 50.65 | -36.38 | 333.38 | -87.04 |
|
Book Value Growth (%)
|
-4.71 | 70.28 | 2.00 | -4,203.16 | -12.72 |
Valuation Ratios
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.22 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
1.97 | 30.19 | 8.16 | 245.29 | 8.85 |
|
Dividend Yield (%)
|
5.59 | 0.49 | 1.91 | 2.35 | 2.23 |
|
EV/EBITDA
|
16.64 | 27.74 | 22.18 | 23.74 | 30.57 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.67 | 1.17 | 0.44 | -10.53 | 1.11 |
|
Short term debt to equity ratio
|
0.03 | 0.06 | 0.11 | -1.41 | 0.09 |
|
Current Ratio
|
1.42 | 1.39 | 1.02 | 0.81 | 1.35 |
|
Quick Ratio
|
1.10 | 1.00 | 0.74 | 0.69 | 1.14 |
|
Interest Coverage
|
2.57 | 30.52 | 23.23 | 5.45 | 3.43 |
Operating Efficiency Ratios
| Pfizer (PFE) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.31 | 29.18 | 19.11 | 20.94 | 18.94 |
|
Asset Turnover
|
0.26 | 0.49 | 0.40 | 0.37 | 0.42 |
|
Receivable days
|
89.35 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
244.44 | 352.51 | 160.77 | 91.61 | 128.14 |
|
Payable days
|
123.59 | 142.23 | 134.61 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
210.20 | 303.95 | 96.16 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
